Variant: rs121913250 

    present in Gene: NRAS
    present in Chromosome: 1
    Position on Chromosome: 114716127
    Alleles of this Variant: C/A;G;T

rs121913250 in NRAS gene and Colorectal Neoplasms PMID 20619739 2010 Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

PMID 16273091 2006 BRAF mutation predicts sensitivity to MEK inhibition.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 21729679 2011 Development of molecular biomarkers in individualized treatment of colorectal cancer.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 21829508 2011 PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

PMID 21305640 2011 Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

PMID 20736745 2010 NRAS mutations are rare in colorectal cancer.

PMID 17699718 2007 AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.

rs121913250 in NRAS gene and Cutaneous Melanoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913250 in NRAS gene and Gastric Adenocarcinoma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913250 in NRAS gene and Juvenile Myelomonocytic Leukemia PMID 10598665 2000 Juvenile myelomonocytic leukemia and Noonan syndrome.

PMID 19047918 2009 Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.

PMID 16518851 2006 Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.

PMID 19966803 2010 A restricted spectrum of NRAS mutations causes Noonan syndrome.

PMID 17384584 2007 Hyperactive Ras in developmental disorders and cancer.

rs121913250 in NRAS gene and Leukemia, Myelocytic, Acute PMID 2278970 1990 RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.

PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

PMID 3122217 1987 RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

PMID 19075190 2009 High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

PMID 22407852 2012 RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

PMID 19657110 2009 Recurring mutations found by sequencing an acute myeloid leukemia genome.

PMID 16434492 2006 Implications of NRAS mutations in AML: a study of 2502 patients.

rs121913250 in NRAS gene and MYELODYSPLASTIC SYNDROME PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913250 in NRAS gene and Malignant Uterine Corpus Neoplasm PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913250 in NRAS gene and Multiple Myeloma PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

rs121913250 in NRAS gene and Myeloid Leukemia, Chronic PMID 23134356 2012 Progression of RAS-mutant leukemia during RAF inhibitor treatment.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs121913250 in NRAS gene and Non-Small Cell Lung Carcinoma PMID 18948947 2008 Somatic mutations affect key pathways in lung adenocarcinoma.

PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.

PMID 23515407 2013 Characteristics of lung cancers harboring NRAS mutations.

PMID 18794081 2008 Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

rs121913250 in NRAS gene and Noonan Syndrome PMID 19966803 2010 A restricted spectrum of NRAS mutations causes Noonan syndrome.

PMID 16518851 2006 Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.

PMID 17384584 2007 Hyperactive Ras in developmental disorders and cancer.

PMID 19047918 2009 Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.

PMID 10598665 2000 Juvenile myelomonocytic leukemia and Noonan syndrome.

rs121913250 in NRAS gene and melanoma PMID 20179705 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

PMID 23414587 2013 MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

PMID 2674680 1989 N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

PMID 20130576 2010 RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

PMID 18390968 2008 Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

PMID 23614898 2013 Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

PMID 8120410 1994 Ras mutations in human melanoma: a marker of malignant progression.

PMID 16291983 2005 Distinct sets of genetic alterations in melanoma.